EC Cardiology

Review Article Volume 10 Issue 5 - 2023

Beyond ACE Inhibitors: Exploring the Benefits of Angiotensin Receptor-Neprilysin Inhibitors in Managing HFrEF

Joshua D-M Elmore-OMS II, Briana M Rivas, Leonard B Goldstein* and James F Keane

A.T. Still University, School of Osteopathic Medicine, USA

*Corresponding Author: Leonard B Goldstein, A.T. Still University, School of Osteopathic Medicine, USA
Received: January 13, 2024; Published: February 01, 2024




Around 115 million people in the US suffer from hypertension, 100 million are obese, 92 million have prediabetes, 26 million have diabetes, and 125 million have atherosclerotic CVD, all of which are high-risk factors that contribute to the development of HF [41]. As a result, a considerable number of the US population can be classified as either at risk of HF or in stage A HF. Common causes of HF include ischemic heart disease, myocardial infarction (MI), hypertension, and valvular heart disease (VHD) [41]. The traditional pharmacotherapy for HF has mainly targeted chronic HF with reduced ejection fraction (HFrEF) and includes angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), β-blockers (BB), and mineralocorticoid receptor antagonists (MRAs). Despite the effectiveness of ACE inhibitors, a new therapy called angiotensin receptor-neprilysin inhibitors (ARNI) have surfaced and demonstrated encouraging outcomes comparable to ACE inhibitors. This poses questions about whether ACE inhibitors or ARNIs are superior in the management of HFrEF. This review focuses on the clinical effectiveness of ACE inhibitors and ARNI in the management of HFrEF.

 Keywords: Heart Failure with Reduced Ejection Fraction; Ace Inhibitor; Enalapril; Angiotensin Receptor-Neprilysin Inhibitor; Sacubitril/Valsartan; Cardiac Failure; Congestive Heart Failure

  1. Go AS., et al. “Heart disease and stroke statistics-2013 update: a report from the American Heart Association”. Circulation1 (2013): e6-245.
  2. Roger VL. “Epidemiology of heart failure”. Circulation Research 6 (2013): 646-659.
  3. Ni H and Xu J. “Recent trends in heart failure-related mortality: United States, 2000-2014”. NCHS Data Brief 231 (2015): 1-8.
  4. Mentz RJ and O’Connor CM. “Pathophysiology and clinical evaluation of acute heart failure”. Nature Reviews Cardiology 1 (2016): 28-35.
  5. Yancy CW., et al. “2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines”. Circulation 128 (2013): e240-327.
  6. Marti CN., et al. “Endothelial dysfunction, arterial stiffness, and heart failure”. Journal of the American College of Cardiology 16 (2012): 1455-1469.
  7. Tsai SH., et al. “Interpretation and use of natriuretic peptides in non-congestive heart failure settings”. Yonsei Medical Journal 2 (2010): 151-163.
  8. Udelson JE and Stevenson LW. “The future of heart failure diagnosis, therapy, and management”. Circulation 25 (2016): 2671-2686.
  9. Schiff GD., et al. “Decompensated heart failure: symptoms, patterns of onset, and contributing factors”. American Journal of Medicine 8 (2003): 625-630.
  10. Fallick C., et al. “Sympathetically mediated changes in capacitance: redistribution of the venous reservoir as a cause of decompensation”. Circulation: Heart Failure 5 (2011): 669-675.
  11. Fonarow GC., et al. “Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure”. Journal of the American College of Cardiology 19 (2007): 1943-1950.
  12. Wang CS., et al. “Does this dyspneic patient in the emergency department have congestive heart failure?” Journal of the American Medical Association15 (2005): 1944-1956.
  13. Zarrinkoub R., et al. “The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden”. European Journal of Heart Failure 9 (2013): 995-1002.
  14. “The NETWORK investigators: Clinical outcome with enalapril in symptomatic chronic heart failure a dose comparison”. European Heart Journal 3 (1998): 481-489.
  15. Pitt D. “Ace inhibitor co-therapy in patients with heart failure: rationale for the randomized aldactone evaluation study (RALES)”. European Heart Journal 16 (1995): 107-110.
  16. Yancy CW., et al. “2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America”. Circulation6 (2017): e137-e161.
  17. “Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction” (2016).
  18. Shearer F., et al. “Renin-angiotensin-aldosterone system inhibitors in heart failure”. Clinical Pharmacology and Therapeutics 4 (2013): 459-467.
  19. Packer M., et al. “Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure”. Circulation1 (2015): 54-61.
  20. Raphael C., et al. “Limitations of the New York heart association functional classification system and self-reported walking distances in chronic heart failure”. Heart4 (2007): 476-482.
  21. CONSENSUS Trial Study Group. “Effects of enalapril on mortality in severe congestive heart failure”. New England Journal of Medicine 23 (1987): 1429-1435.
  22. Lubitz SA., et al. “Atrial fibrillation in congestive heart failure”. Heart Failure Clinic 2 (2010): 187-200.
  23. De Ferrari GM., et al. “Atrial fibrillation in heart failure patients: prevalence in daily practice and effect on the severity of symptoms: data from the ALPHA study registry”. European Journal of Heart Failure 5 (2007): 502-509.
  24. Bigger JT. “Why patients with congestive heart failure die: arrhythmias and sudden cardiac death”. Circulation5 (1987): 28-35.
  25. SOLVD Investigators., et al. “Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure”. New England Journal of Medicine 5 (1991): 293-302.
  26. McMurray JJV., et al. “Angiotensin-neprilysin inhibition versus enalapril in heart failure”. New England Journal of Medicine 11 (2014): 993-1004.
  27. Desai AS., et al. “Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients”. European Heart Journal 30 (2015): 1990-1997.
  28. Packer M., et al. “Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure”. Circulation1 (2015): 54-61.
  29. Troughton RW., et al. “Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis”. European Heart Journal 23 (2014): 1559-1567.
  30. Daniels LB., et al. “How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study”. American Heart Journal 5 (2006): 999-1005.
  31. Frigerio M and Roubina E. “Drugs for left ventricular remodelling in heart failure”. American Journal of Cardiology 12A (2005): 10-18.
  32. Shearer F., et al. “Renin-angiotensin-aldosterone system inhibitors in heart failure”. Clinical Pharmacology and Therapeutics 4 (2013): 459-467.
  33. Pahor M., et al. “Enalapril prevents cardiac fibrosis and arrhythmias in hypertensive rats”. Hypertension 2 (1991): 148-157.
  34. Goussev A., et al. “Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure”. American Journal of Physiology 275 (1998): 626-631.
  35. Dibianco R. “Ace inhibitors in the treatment of heart failure”. Clinical Cardiology 6 (1990): 32-38.
  36. Menendez JT. “The mechanism of action of LCZ696”. Cardiac Failure Review 1 (2016): 40-46.
  37. Richardson J., et al. “A new mechanism of action in heart failure”. Journal of Pharmacy Technology 3 (2016): 116-124.
  38. Vardeny O., et al. “Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure”. JACC: Heart Failure 6 (2014): 663-670.
  39. “Sacubitril/Valsartan (Entresto) for heart failure”. Journal of the American Medical Association 314 (2015): 722-723.
  40. von Lueder TG., et al. “Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure”. Circulation: Heart Failure 3 (2013): 594-605.
  41. Katzung BG and Vanderah TW. “Basic and Clinical Pharmacology”. 15th McGraw Hill (2021).
  42. 2022 by the American Heart Association, Inc., the American College of Cardiology Foundation, and the Heart Failure Society of America (2022).
  43. Kitamura K., et al. “Cloning and characterization of cDNA encoding a precursor for human adrenomedullin”. Biochemical and Biophysical Research Communications 2 (1993): 720-725.

Leonard B Goldstein., et al. "Beyond ACE Inhibitors: Exploring the Benefits of Angiotensin Receptor-Neprilysin Inhibitors in Managing HFrEF." EC Cardiology 10.5 (2023): 01-08.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net